skip to the content
  • Rak v Sloveniji 2007, Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2010
  • M. Primic Žakelj in sod. Preživetje bolnikov z rakom, zbolelih v letih 1991-2005 v Sloveniji; Ljubljana: Onkološki inštitut, 2009
  • J. Ferlay, P Autier, M. Boniol in sod. Estimates of the cancer incidence and mortality in Europe 2006. Annals of Oncology 2007; 18: 581-592.
  • Verdecchia A, Francisci S, Brenner H in sod. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncology 2007; 8:784-796
  • S. Novaković in sodelavci. ONKOLOGIJA – raziskovanje, diagnostika in zdravljenje raka: Mladinska knjiga 2009
  • Quinn MJ, d’Onofrio A, Moller B in sod. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol 2003; 14:1148-1152.
  • Stewart BW, Kleihues P (Eds). World Cancer Report. IARC Press, Lyon, 2003.
  • Čufer T. Sistemsko zdravljenje raka: dejstva in pričakovanja. Zdravniški vestnik 2007; 76:801-806.
  • Snoj N, Čufer T. Biološko in tarčno zdravljenje karcinomov. Onkologija 2007; 1:72-76.
  • Štrukelj B. Biološka zdravila, Biotehnologija v farmaciji in medicini. Roche farmacevtska družba d.o.o. 2007; 8-21
  • Pajk B. Podporno zdravljenje pri bolnikih z rakom. Zbornik prispevkov Fajdigovi dnevi, Kranjska gora, 14.-15.10.2005; 73-80.
  • Krajc M, Primic Žakelj M. Priprava na državni program presejanja raka dojk (DORA). Onkologija 2007; 1:4-9.
  • Verdecchia A, Francisci S, Brenner H in sod. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet 2007; 8:784-796.
  • Hurwitz H, Fehrenbacher L, Novotny W in sod. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
  • Gianonio B, Catalano PJ, Meropol NJ in sod. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin for previously treated metastatic colorectal cancer. J Clin Oncol 2007; 25:1539-1544.
  • Miller K, Wang M, Gralow J in sod. Paclitaxel plus bevacizumab versus paclizaxel alone for metastatic berast cancer. N Engl J Med 2007; 357:2666-76.
  • Sandler A, Gray R, Perry MC in sod. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 2006; 355:2542-50.
  • Escudier B, Pluzanska A, Koralewski P in sod. Bevacizumab plu interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trail. Lancet 2007; 370(9605):2071-3.
  • Romond E, Perez E, Bryant J in sod. Trastzumab plus Adjuvant Chemotherapy for Operable HER2 positive Breast Cancer. N Engl J Med 2005; 353: 1673-1684.
  • Piccart M, Procter M, Leyland Jones B in sod. Trastzumab after Adjuvant Chemotherapy in Her2 Positive Breast Cancer. N Engl J Med 2005; 353: 1659-1672.
  • Schulz H, Bohlius JF, Trelle S in sod. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99(9):706-14.
  • Feugier P, Van Hoof A, Sebban C in sod. Long Term Results of the R-CHOP Study in the Treatment of Eldery Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-4126.
  • Van Oers MHJ, Klasa R, Marcus RE in sod. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006; 108:3295-301.
  • Shepherd FA, Rodriguez Pereira J, Ciuleanu T in sod. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
  • Moore MJ, Goldstein D, Hamm J in sod. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2007; 25:1960-1966
  • Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy trial: overview of efficacy, safety and costs-effectiveness. Clin Colorectal Cancer 2006; 6:278-287.
  • Body JJ, Diel IJ, Bell R in sod. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111:306-12.